INTENDED
nasal in antigens virus B influenza and antigens virus A influenza detect To
assist to (swab pharyngeal or mucus nasal/discharge nasal, swab nasal, aspirate
.(disease infectious virus influenza of diagnosis the in TEST THE OF EXPLANATION AND SUMMARY 3 about in resulting, epidemics seasonal in world the around spreads Influenza annual 000,650 to 000,290 about and illness severe of cases annual million 5 to (2017, Release News WHO. (years pandemic some in millions to rising, deaths ,headache, pains muscle, throat sore, fever, chills are symptoms Common.discomfort general and fatigue/weakness, coughing those to similar be can symptoms initial the because difficult is Diagnosis.

Capilia tb ag

Capilia tb ag

agents infectious other by caused most the with associated is and prevalent more usually is virus A influenza The more present usually infections B influenza while, epidemics influenza serious.symptoms mild and diagnosis rapid, contagious highly is virus influenza the Because ability the And. health public on effect positive a have can treatment prompt an prescribe to physician the help can antigens B or A between distinguish to .therapy antiviral appropriate
is onset symptom of hours 48 within therapy antiviral of Administration
.shedding viral reduce to and symptoms of reduction rapid more for recommended or/and A influenza of detection accurate and rapid provide can Neo Flu Capilia equipment or instruments special No. patients symptomatic from antigens virus B .required a

Capilia tb neo

Capilia tb neo

Description:

INTENDED USE

To detect influenza A virus antigens and influenza B virus antigens in nasal aspirate, nasal swab, nasal discharge/nasal mucus or pharyngeal swab (to assist in the diagnosis of influenza virus infectious disease).

SUMMARY AND EXPLANATION OF THE TEST

Influenza spreads around the world in seasonal epidemics, resulting in about 3 to 5 million annual cases of severe illness and about 290,000 to 650,000 annual deaths, rising to millions in some pandemic years. (WHO News Release, 2017)

Common symptoms are chills, fever, sore throat, muscle pains, headache, coughing, weakness/fatigue and general discomfort.

Diagnosis is difficult because the initial symptoms can be similar to those caused by other infectious agents.

The influenza A virus is usually more prevalent and is associated with the most serious influenza epidemics, while influenza B infections usually present more mild symptoms.

Because the influenza virus is highly contagious, rapid diagnosis and prompt treatment can have a positive effect on public health. And the ability to distinguish between A or B antigens can help the physician to prescribe an appropriate antiviral therapy.

Administration of antiviral therapy within 48 hours of symptom onset is recommended for more rapid reduction of symptoms and to reduce viral shedding.

Capilia Flu Neo can provide rapid and accurate detection of influenza A and/or B virus antigens from symptomatic patients. No special instruments or equipment are required.

  • Provides fast and reliable results
  • Easy to read
  • Created through the latest nanotechnology “Platinum-Gold Colloid”
  • Includes an extraction buffer that is compatible with Capilia 1 series tests (Flu, Adeno, hMPV, RSV)

REAGENTS AND MATERIALS PROVIDED

  • Test cartridges
  • Extraction buffer (compatible with 4 different tests)
  • Drip tips
  • Nasal swab

REPORTING TIME

3-5 minutes

PRINCIPLE OF THE TEST

Measurement using this product is based on an immunochromatography assay using a monoclonal antibody that recognizes influenza virus antigens.

This product comprises a test plate with a carrier strip containing a sample placement area, a reagent area including a colloidal platinum-gold labeled anti-influenza A and B virus monoclonal antibody (mouse) (hereinafter referred to as “colloidal platinum-gold labeled antibody” ), a reading area [A] that fixes the anti-influenza A virus monoclonal antibody (mouse) (hereinafter referred to as “anti-influenza A virus antibody” ), a reading area [B] that fixes the anti-influenza B virus monoclonal antibody (mouse) (hereinafter referred to as “anti-influenza B virus antibody” ), and a reading area [C] that fixes the anti-mouse immunoglobulin polyclonal antibody (rabbit) (hereinafter referred to as “anti-mouse immunoglobulin antibody” ).

Capilia tb ag

Capilia tb ag

Product Summary

  • Kit contents :
    Test Plate×10, Extraction Buffer 0.7mL×10, Nozzle×10, Nasal Swab×10
  • Validity  27 months
  • Storage  store at 2-30℃
  • Detection time  3-5 minutes
  • Positive Control (Sold Separately)
    Kit contents: Positive Control Flu A 1.0mL 1vial, Positive Control Flu B 1.0mL 1vial
  • Validity 12 months
  • Storage Store at 2-8℃
  • Positive Control Flu Procedure

 

 

rtTA (Neo) , Lentiviral particles
LVP400-Neo 1x107 IFU/ml x 200ul
EUR 404
Description: Pre-made lentiviral particles expressing reverse tetracycline Transcriptional Activator (rtTA) under enhanced EF1a promoter with Neomycin antibioic marker, provided in DMEM medium with 10% FBS.
CMV-TetR (Neo) Lentiviral particles 
LVP017-Neo 1x107 IFU/ml x 200ul
EUR 404
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under CMV promoter, with Neomycin antibiotic marker.
β-Lactamase (Neo) lentiviral particles
LVP335-Neo 1x107 IFU/ml x 200ul
EUR 349
Description: pre-made lentiviral particles expressing β-Lactamase gene. A Neomycin marker was expressed under RSV promoter. Particles is provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.
EF1a-TetR (Neo) Lentiviral particles 
LVP459-Neo 1x107 IFU/ml x 200ul
EUR 404
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under enhanced EF1a promoter with Neomycin antibioic marker.
LoxP GFP/RFP ColorSwitch (Neo) lentivirus
LVP460-Neo 1x107 IFU/ml x 200ul
EUR 710
Description: Pre-made lentiviral particles expressing "LoxP-GFP-stop-LoxP-RFP-Stop" cassette under suCMV promoter. It also contains a Neomycin antibiotic selection marker under Rsv promoter. Virus is provided in DMEM medium with 10% FBS and 60ug/ml of polybrene.
pWZL-Neo Retroviral Vector
RTV-001-NEO 10 ?g
EUR 566
Description: Use this construct to clone your gene for downstream recombinant retroviral packaging
SV40 large T-antigen (Neo), CMV lentiviral particles
LVP016-Neo 1x107 IFU/ml x 200ul
EUR 349
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under suCMV promoter, containing Neomycin marker.
SV40 large T-antigen (Neo), EF1a lentiviral particles
LVP557-Neo 1x107 IFU/ml x 200ul
EUR 349
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under EF1a promoter, containing Neomycin marker.
EF1a Control lentiviral particles (Neo)
EF1a-Null-Neo 1 x107 IFU/ml x 200ul
EUR 349
Description: Negative control lentivirus contains a null spacer insert under EF1a promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter.
CMV Control lentiviral particles (Neo)
CMV-Null-Neo 1 x107 IFU/ml x 200ul
EUR 349
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter.
hTERT (CMV, Neo) lentivirus in PBS
LVP1130-Neo-PBS 1x108 IFU/ml x 200ul
EUR 710
Description: Concentrated lentivirus in PBS, expressing human TERT gene under suCMV promoter, containing Neomycin marker.
hTERT (EF1a, Neo) lentivirus in PBS
LVP1131-Neo-PBS 1x108 IFU/ml x 200ul
EUR 710
Description: Concentrated lentivirus in PBS, expressing human TERT gene under EF1a promoter, containing Neomycin marker.
rtTA (Neo) in PBS, Lentiviral particles
LVP400-Neo-PBS 5x107 IFU/ml x 200ul
EUR 507
Description: Pre-made lentiviral particles expressing reverse tetracycline Transcriptional Activator (rtTA) under enhanced EF1a promoter with Neomycin antibioic marker, concentrated particles provided in PBS solution.
Color Switch, CRE report cell line: HEK293-loxP-GFP-RFP Neo)
SC018-Neo 2x10E6 cell/ml x1ml
EUR 4400
Description: CRE reporter cell line (Neo): HEK293 cell line expressing "LoxP-GFP-stop-LoxP-RFP" cassette with Neomycin antibiotic marker
CMV-TetR (Neo) Lentiviral particles  in PBS
LVP017-Neo-PBS 5x107 IFU/ml x 200ul
EUR 507
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under CMV promoter, with Neomycin antibiotic marker. Particles pellet was re-suspended in PBS solution.
EF1a-TetR (Neo) Lentiviral particles  in PBS
LVP459-Neo-PBS 5x107 IFU/ml x 200ul
EUR 507
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under enhanced EF1a promoter with Neomycin antibioic marker. Particles was pellet down and re-suspended in PBS solution.
LoxP GFP/RFP ColorSwitch (Neo) lentivirus (concentrated)
LVP460-Neo-PBS 5x107 IFU/ml x 200ul
EUR 862
Description: Pre-made lentiviral particles expressing "LoxP-GFP-stop-LoxP-RFP-Stop" cassette under suCMV promoter. It also contains a Neomycin antibiotic selection marker under Rsv promoter. Virus was provied in PBS solution.
SV40 large T-antigen (Neo) in PBS, CMV lentiviral particles
LVP016-Neo-PBS 5x107 IFU/ml x 200ul
EUR 710
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under suCMV promoter, containing Neomycin marker, provided in PBS solution.
SV40 large T-antigen (Neo) in PBS, EF1a lentiviral particles
LVP557-Neo-PBS 5x107 IFU/ml x 200ul
EUR 710
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under EF1a promoter, containing Neomycin marker, provided in PBS solution.
EF1a Control lentiviral particles (Neo) in PBS
EF1a-Null-Neo-PBS 1 x108 IFU/ml x 200ul
EUR 710
Description: Negative control lentivirus contains a null spacer insert under EF1a promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter. The virus was concentrated and provided in PBS solution.
CMV Control lentiviral particles (Neo) in PBS
CMV-Null-Neo-PBS 1 x108 IFU/ml x 200ul
EUR 710
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter. The virus was concentrated and provided in PBS solution.
Porcine Swine FLU virus A (FLU A) ELISA Kit
QY-E40037 96T
EUR 400
Human FLU ELISA Kit
EHF0241 96Tests
EUR 521